Montelukast För Barn Från 6 Till 14 År Accord

Montelukast, the active ingredient in Montelukast För Barn Från 6 Till 14 År Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis in children aged six to fourteen years.

GNH USA supplies Montelukast För Barn Från 6 Till 14 År Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic respiratory and allergic conditions in children.

Asthma: reduces the frequency of bronchoconstriction episodes and improves overall lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal allergies. Exercise‑induced bronchospasm: helps prevent airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nasopharyngitis: mild upper‑respiratory infection. - Rash: mild skin irritation. - Fever: low‑grade temperature elevation.

Serious or Rare Side Effects: - Mood changes: depression or suicidal thoughts. - Allergic reactions: hives, swelling, or anaphylaxis. - Hepatotoxicity: abnormal liver enzymes. - Stevens‑Johnson syndrome: severe skin eruption. - Angioedema: rapid swelling of face or throat. - Blood dyscrasias: rare blood count abnormalities.

Montelukast should be used with awareness of specific safety considerations.

Dose adjustment: follow the prescriber's recommendation for age and weight. Monitor mood: watch for signs of depression or suicidal ideation. Liver function: assess hepatic enzymes in patients with known liver disease. Drug interactions: review concomitant medications for potential CYP450 effects. Pregnancy and lactation: discuss risks with a healthcare professional before use. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Montelukast may interact with other medicines that influence the CYP450 system or share similar therapeutic effects.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma levels. - Rifampin: strong enzyme inducer that can lower efficacy. - St. John’s wort: may decrease drug exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect. - Zafirlukast or other leukotriene modifiers: additive pharmacologic effect. - Antidepressants: monitor for mood changes when combined.